MONTRÉAL, Nov. 23,
2012 /CNW/ - Aptilon Corporation ("Aptilon" or the
"Corporation") (TSXV: APZ) today announced that its
wholly-owned subsidiary, Aptilon Holdings Inc. ("Holdings"), has
concluded the sale of substantially all of its assets related to
its business of providing multichannel, e-detailing and physician
marketing services to members of the healthcare industry (the
"Business") to Indegene Aptilon, Inc. ("Indegene"), an entity
dealing at arm's length with Aptilon and Holdings.
The sale of these assets will allow Aptilon to
focus its activities on the healthcare marketing services it
acquired in September 2009. The Board
of Directors of Aptilon remains the same after this transaction,
and it is comprised of: Justin
Beckett, Mark Benthin, André
Brosseau, Roger Korman and
Denis Martineau.
The Corporation also announces that it has
reached agreements with its Canadian lenders regarding the
repayment of its long-term debt. The revised payment schedule
coincides with the earnout payments that may be received from
Indegene in June 2013 and
June 2014 pursuant to the Asset
Purchase Agreement. In addition, the loan granted by FIER
CPVC-Montreal has been reimbursed in full.
The Corporation anticipates being able to file
the missing annual and quarterly financial statements with the
regulatory authorities by the end of this year, and it understands
that the current cease-trade orders should be lifted shortly after
the filings. The Corporation anticipates being in a position to
hold its annual meeting of shareholders by the end of February 2013.
About Aptilon Corporation
Aptilon enables pharmaceutical, biotech and medical device
companies to effectively reach, message, connect and interact with
US physicians and healthcare professionals via multiple access
channels. Its innovative service offerings provide targeted
impressions and interactions through: video and mobile detailing,
digital access channels and permission-based email services. Top
pharmaceutical companies and respected healthcare organizations
have adopted Aptilon's solutions to market to, engage and interact
with leading healthcare practitioners. For more information, visit
www.aptilon.com.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as such term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
SOURCE Aptilon Corporation
